AidaBreast is a test that assesses the 10-year locoregional invasive breast cancer recurrence risk and predicts adjuvant treatment benefit.

PreludeDx has completed rigorous validations (analytical and clinical) of its novel, multi-omic invasive breast cancer test, AidaBreast.

AidaBreast is now available. Please fill out the following form to be contacted.

The test results for each patient are the outcome of a risk algorithm that combines multi-omic protein and RNA biomarker expression to calculate an individualized score that aids in shared treatment decisions.